The PRISMAP call 5 for user projects is now open and we invite you all to start preparing your proposals! 

The application procedure,guide for applicants as well as the radionuclide and service portfolio remain unchanged. 

Deadline for submission to this call is 15 Oct 2024 and the online submission portal will be opened end of August. 

Hearings for proposals passing the evaluation threshold will take place on 19 Nov 2024. We strive to complete the evaluation process by 15 Dec 2024 so that the selected projects can start in early 2025. All projects need to be completed by 30 Sep 2025. 

Priorities for selection shall be given to SME candidates, or proof-of-concept experiments with 1 or 2 deliveries, in preparation of an initial clinical pilot phase in humans taking place after PRISMAP. 

In preparation of your proposal, we strongly recommend that all applicants get in contact with us via our helpdesk to discuss their user project idea. In fact, most successful PRISMAP user projects have gone this route, and we will be happy to provide you with a personal PRISMAP mentor for your project application. 

We are looking forward to your proposal ideas!

Meet PRISMAP in Nantes on 18 Sep 2024! Our rich one-day PRISMAP public event will include news about PRISMAP, reports by PRISMAP users about their projects and scientific sessions about radiochemistry and nuclear medicine made in Nantes. For details and registration please visit our event page. 

Save the Date! We are happy to announce our upcoming webinar to celebrate International Women's Day in Radiopharmaceutical Sciences! Join us on 19 August 2024 at 14h CEST as we will highlight contributions of women in advancing this vital field. Stay tuned for more details!

We have released our fourth newsletter today. 

Selected features of this newsletter are available on our website. 

If you would like to receive the newsletter directly in your mailbox, please join our PRISMAP community.

A wonderful opportunity today to show the MEDICIS facility to David Townsend the inventor of the first PET-CT system. The first combined PET/CT scanner was developed by David Townsend (at the University of Geneva) and Ronald Nutt (at CPS Innovationsin Knoxville, TN) in 1992 resulting in the installation of the first prototype for clinical evaluation, funded by the NCI, at the University of Pittsburgh medical center in 1998.

The PET-CT scanner has revolutionised medical diagnosis in many fields, by adding precision of anatomic localisation to functional imaging and was honored by Time Magazine as the “Medical Science Invention of the Year” in 2000. 

In honour of the World Cancer Day and aligned with the 2024 theme “Close the care gap” that celebrates cancer treatment progress in its many forms, PRISMAP is proud to host a dedicated webinar on 5 Feb 2024, 14.00-15.00 CET.

This event will specifically spotlight the latest advancements in both preclinical and clinical cancer research within the PRISMAP consortium.

Join us as we celebrate progress, share insights and foster collaboration in the fight against cancer.

The three following presentations have been confirmed: 

- Dr Asta Juzeniene, UiO: "Exploring the efficacy of 212Pb, 225Ac and 177Lu targeted radionuclides for cancer therapy: In vitro and in vivo assessments”

- Koen Vermeulen, SCK CEN: "Exploring the potential of targeted radionuclide therapy with [153Sm]Sm-DOTA-TATE: a preclinical approach"

- Clarita Saldarriaga Vargas, SCK CEN: "Computational models of mouse kidney tissues to investigate the influence of absorbed dose heterogeneity in nephrotoxicity in radiopharmaceutical therapy"

The webinar page is available here. 

The PRISMAP information portal is now available. 

This portal gathers documents providing information on specifications, standard practices and regulations relevant for the following major fields and topics addressed by PRISMAP:

• Nuclear decay data
• Production of radionuclides
• Development and Preparation of Radiopharmaceuticals
• Specifications and Quality Control/Metrology
• Radioprotection/Transport Issues

The uploaded information relies on knowledge acquired or produced within the PRISMAP network, but links to entities with relevant information not available in PRISMAP documents are also provided.

It is in tune with the PRISMAP`s goal to standardize and harmonize research and development activities with novel radionuclides within and outside PRISMAP network, while providing guidance for their clinical translation, namely to pharmaceutical authorities and policy makers at the European and national levels.

Enjoy browsing!

A job opportunity in Radionuclide Production is available at King’s College London!

For the advert please refer to the KCL website

We proudly present the first publication by a user project which received our PRISMAP services. 

Outcomes of the project entitled "Added Value using Terbium-161 over Lutetium-177 in Combination with the metabolically more stable GRPR Ligand AMTG for Targeted Radiotherapy of GRPR-expressing Malignancies? – A Preclinical Evaluation", led by Dr. rer. nat. Thomas Günther from Technical University of Munich, Germany have just been published in JNM. 

Enjoy reading!

A new cyclotron has just been installed at the National Centre for Nuclear Research (NCBJ) which will allow to produce radionuclides which have not been produced at NCBJ to date and have not been widely available in Poland. Thanks to this new device, it will be possible to conduct research on new radiopharmaceuticals, in particular those that will be specially designed for the needs of individual patients.

To learn more about it

On 28 Nov 2023 we organised an in-person public event at the Lisbon School of Medicine, entitled "Challenges in nuclear medicine".

In the first session Portuguese and Spanish researchers presented their recent findings and invited to discuss challenges in nuclear medicine.

In the second session PRISMAP news, results from the project and its user projects and needs of the User Forum were in the focus.

For those who were not able to join us in Lisbon, the presentations and a summary of the round table discussion are now available on the event page. 

A report recently published by the OECD's Nuclear energy agency (NEA) comes to the conclusion that International collaboration is key for the success of nuclear medicine.

Expecting the demand for new diagnostic and therapeutic radioisotopes to increase, the agency calls for international collaboration and the promotion and involvement of young talents in the field. 

PRISMAP shares this view and is committed to achieving these goals.

We are just back from a consortium meeting in Lisbon, wonderfully hosted by our colleagues from Instituto Superior Técnico de Lisboa. 

We enjoyed three days of intense discussions of the project progress so far, the next steps within the project and sustainability beyond PRISMAP. 

We also took the opportunity to invite the medical community to join us for a public day, learn about our user projects and novel avenues in nuclear medicine. In the first session Portuguese and Spanish researchers presented their recent findings and invited to discuss challenges in nuclear medicine. In the second session PRISMAP news, results from the project and its user projects and needs of the User Forum were in the focus. 

Walks through beautiful Lisbon plus pasteis de nata, cataplana and many other Portuguese delicacies rounded off the pleasure.

The selective production of exotic species (SPES) project aims to construct at Legnaro National Laboratories (LNL) a new facility for the production of radioactive ion beams (RIBs) according to the isotope separation on line (ISOL) technique. In the specific case of the SPES facility, a multi-foil uranium carbide target is impinged by a 40 MeV, 200 µA proton beam generated by a cyclotron proton driver. In these conditions, a fission rate of approximately 10¹³ fissions per second is expected in the target. Then, the ²³⁸U fission fragments are delivered to the ion source: here they can be ionized and subsequently accelerated toward the experimental areas.

On 31 October 2023, the first stable ion beam was produced inside the SPES ISOL bunker. In particular, making use of a FEBIAD Ion Source, the INFN staff produced 400 nA (mainly N1+ and CO1+) @ 50 keV. The ISOL machine proved to be stable and reliable for the entire duration of the tests.

This is the first important step towards reaching the first radioactive beam. The consolidation of the ISOL machine with stable beams will continue during the next months.